annual net income:
-$535.60M-$4.16B(-114.80%)Summary
- As of today (April 25, 2025), VRTX annual net profit is -$535.60 million, with the most recent change of -$4.16 billion (-114.80%) on December 31, 2024.
- During the last 3 years, VRTX annual net income has fallen by -$2.88 billion (-122.87%).
- VRTX annual net income is now -114.80% below its all-time high of $3.62 billion, reached on December 31, 2023.
Performance
VRTX Net income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly net income:
$913.00M-$132.40M(-12.67%)Summary
- As of today (April 25, 2025), VRTX quarterly net profit is $913.00 million, with the most recent change of -$132.40 million (-12.67%) on December 31, 2024.
- Over the past year, VRTX quarterly net income has dropped by -$55.80 million (-5.76%).
- VRTX quarterly net income is now -41.12% below its all-time high of $1.55 billion, reached on December 31, 2018.
Performance
VRTX quarterly net income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM net income:
-$535.60M-$55.80M(-11.63%)Summary
- As of today (April 25, 2025), VRTX TTM net profit is -$535.60 million, with the most recent change of -$55.80 million (-11.63%) on December 31, 2024.
- Over the past year, VRTX TTM net income has dropped by -$4.16 billion (-114.80%).
- VRTX TTM net income is now -113.33% below its all-time high of $4.02 billion, reached on March 31, 2024.
Performance
VRTX TTM net income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Net income Formula
Net Income = Revenue − COGS − Operating Expenses − Interest − Taxes − Other Expenses
VRTX Net income Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -114.8% | -5.8% | -114.8% |
| 3 y3 years | -122.9% | -1.9% | -116.4% |
| 5 y5 years | -145.5% | -1.9% | -116.4% |
VRTX Net income Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -114.8% | at low | -17.0% | +125.4% | -113.3% | at low |
| 5 y | 5-year | -114.8% | at low | -17.0% | +125.4% | -113.3% | at low |
| alltime | all time | -114.8% | +29.0% | -41.1% | +125.4% | -113.3% | +30.0% |
Vertex Pharmaceuticals Incorporated Net income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$535.60M(-114.8%) | $913.00M(-12.7%) | -$535.60M(+11.6%) |
| Sep 2024 | - | $1.05B(-129.1%) | -$479.80M(-2.1%) |
| Jun 2024 | - | -$3.59B(-426.8%) | -$489.90M(-112.2%) |
| Mar 2024 | - | $1.10B(+13.5%) | $4.02B(+11.0%) |
| Dec 2023 | $3.62B(+9.0%) | $968.80M(-6.4%) | $3.62B(+4.3%) |
| Sep 2023 | - | $1.04B(+13.1%) | $3.47B(+3.1%) |
| Jun 2023 | - | $915.70M(+30.9%) | $3.36B(+3.2%) |
| Mar 2023 | - | $699.80M(-14.5%) | $3.26B(-1.9%) |
| Dec 2022 | $3.32B(+41.8%) | $818.90M(-12.0%) | $3.32B(+1.5%) |
| Sep 2022 | - | $930.50M(+14.8%) | $3.27B(+2.5%) |
| Jun 2022 | - | $810.50M(+6.4%) | $3.19B(+30.3%) |
| Mar 2022 | - | $762.10M(-1.0%) | $2.45B(+4.7%) |
| Dec 2021 | $2.34B(-13.6%) | $770.10M(-9.6%) | $2.34B(+7.6%) |
| Sep 2021 | - | $851.90M(+1171.5%) | $2.18B(+9.3%) |
| Jun 2021 | - | $67.00M(-89.7%) | $1.99B(-27.9%) |
| Mar 2021 | - | $653.10M(+8.1%) | $2.76B(+1.9%) |
| Dec 2020 | $2.71B(+130.4%) | $604.24M(-9.5%) | $2.71B(+0.8%) |
| Sep 2020 | - | $667.43M(-20.3%) | $2.69B(+29.3%) |
| Jun 2020 | - | $837.27M(+38.9%) | $2.08B(+37.7%) |
| Mar 2020 | - | $602.75M(+3.3%) | $1.51B(+28.4%) |
| Dec 2019 | $1.18B(-43.9%) | $583.22M(+914.0%) | $1.18B(-45.1%) |
| Sep 2019 | - | $57.52M(-78.5%) | $2.14B(-3.2%) |
| Jun 2019 | - | $267.43M(-0.4%) | $2.22B(+2.8%) |
| Mar 2019 | - | $268.63M(-82.7%) | $2.16B(+2.8%) |
| Dec 2018 | $2.10B(+695.8%) | $1.55B(+1104.3%) | $2.10B(+224.1%) |
| Sep 2018 | - | $128.75M(-37.9%) | $647.05M(+55.8%) |
| Jun 2018 | - | $207.36M(-1.4%) | $415.36M(+83.8%) |
| Mar 2018 | - | $210.26M(+108.8%) | $225.99M(-14.2%) |
| Dec 2017 | $263.48M(-335.1%) | $100.68M(-197.8%) | $263.48M(+34.6%) |
| Sep 2017 | - | -$102.95M(-672.1%) | $195.75M(-24.7%) |
| Jun 2017 | - | $18.00M(-92.7%) | $259.86M(+46.5%) |
| Mar 2017 | - | $247.76M(+652.0%) | $177.34M(-258.3%) |
| Dec 2016 | -$112.05M(-79.9%) | $32.95M(-184.8%) | -$112.05M(-48.8%) |
| Sep 2016 | - | -$38.84M(-39.8%) | -$218.73M(-20.5%) |
| Jun 2016 | - | -$64.53M(+55.0%) | -$275.04M(-31.1%) |
| Mar 2016 | - | -$41.63M(-43.5%) | -$399.36M(-28.2%) |
| Dec 2015 | -$556.33M(-24.7%) | -$73.73M(-22.5%) | -$556.33M(-15.6%) |
| Sep 2015 | - | -$95.15M(-49.6%) | -$659.26M(-10.2%) |
| Jun 2015 | - | -$188.85M(-4.9%) | -$734.17M(+4.2%) |
| Mar 2015 | - | -$198.61M(+12.4%) | -$704.70M(-4.6%) |
| Dec 2014 | -$738.55M(+66.0%) | -$176.66M(+3.9%) | -$738.55M(+42.7%) |
| Sep 2014 | - | -$170.06M(+6.7%) | -$517.61M(+9.7%) |
| Jun 2014 | - | -$159.38M(-31.4%) | -$471.69M(+27.7%) |
| Mar 2014 | - | -$232.46M(-624.9%) | -$369.47M(-17.0%) |
| Dec 2013 | -$445.03M(+315.8%) | $44.28M(-135.7%) | -$445.03M(-21.3%) |
| Sep 2013 | - | -$124.13M(+117.1%) | -$565.46M(+13.3%) |
| Jun 2013 | - | -$57.16M(-81.4%) | -$498.87M(-1.5%) |
| Mar 2013 | - | -$308.02M(+304.5%) | -$506.64M(+373.4%) |
| Dec 2012 | -$107.03M(-461.9%) | -$76.15M(+32.3%) | -$107.03M(-183.8%) |
| Sep 2012 | - | -$57.54M(-11.4%) | $127.75M(-68.6%) |
| Jun 2012 | - | -$64.93M(-170.9%) | $406.40M(+36.7%) |
| Mar 2012 | - | $91.59M(-42.3%) | $297.26M(+905.1%) |
| Dec 2011 | $29.57M(-103.9%) | $158.63M(-28.3%) | $29.57M(-109.6%) |
| Sep 2011 | - | $221.11M(-227.0%) | -$309.45M(-58.2%) |
| Jun 2011 | - | -$174.07M(-1.2%) | -$739.51M(-3.4%) |
| Mar 2011 | - | -$176.10M(-2.4%) | -$765.45M(+1.4%) |
| Dec 2010 | -$754.63M(+17.5%) | -$180.39M(-13.7%) | -$754.63M(+3.0%) |
| Sep 2010 | - | -$208.96M(+4.5%) | -$732.88M(+8.8%) |
| Jun 2010 | - | -$200.01M(+21.0%) | -$673.49M(+4.5%) |
| Mar 2010 | - | -$165.27M(+4.2%) | -$644.78M(+0.4%) |
| Dec 2009 | -$642.18M(+39.6%) | -$158.64M(+6.1%) | -$642.18M(+2.6%) |
| Sep 2009 | - | -$149.56M(-12.7%) | -$625.87M(+3.2%) |
| Jun 2009 | - | -$171.30M(+5.3%) | -$606.35M(+15.2%) |
| Mar 2009 | - | -$162.67M(+14.3%) | -$526.37M(+14.5%) |
| Dec 2008 | -$459.85M(+17.5%) | -$142.33M(+9.4%) | -$459.85M(+14.0%) |
| Sep 2008 | - | -$130.04M(+42.4%) | -$403.27M(+6.1%) |
| Jun 2008 | - | -$91.32M(-5.0%) | -$380.26M(-6.5%) |
| Mar 2008 | - | -$96.15M(+12.1%) | -$406.70M(+3.9%) |
| Dec 2007 | -$391.28M | -$85.75M(-19.9%) | -$391.28M(+17.5%) |
| Sep 2007 | - | -$107.03M(-9.1%) | -$332.87M(+19.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2007 | - | -$117.77M(+45.9%) | -$277.64M(+16.9%) |
| Mar 2007 | - | -$80.73M(+195.2%) | -$237.53M(+14.8%) |
| Dec 2006 | -$206.89M(+1.7%) | -$27.34M(-47.2%) | -$206.89M(-5.0%) |
| Sep 2006 | - | -$51.80M(-33.3%) | -$217.68M(-11.3%) |
| Jun 2006 | - | -$77.66M(+55.0%) | -$245.45M(+17.6%) |
| Mar 2006 | - | -$50.09M(+31.4%) | -$208.78M(+2.6%) |
| Dec 2005 | -$203.42M(+22.4%) | -$38.13M(-52.1%) | -$203.42M(-2.2%) |
| Sep 2005 | - | -$79.58M(+94.1%) | -$208.06M(+24.4%) |
| Jun 2005 | - | -$40.99M(-8.3%) | -$167.25M(-1.9%) |
| Mar 2005 | - | -$44.72M(+4.6%) | -$170.53M(+2.6%) |
| Dec 2004 | -$166.25M(-15.5%) | -$42.77M(+10.3%) | -$166.25M(+1.1%) |
| Sep 2004 | - | -$38.77M(-12.4%) | -$164.51M(-22.5%) |
| Jun 2004 | - | -$44.27M(+9.5%) | -$212.16M(-0.7%) |
| Mar 2004 | - | -$40.44M(-1.4%) | -$213.69M(+40.0%) |
| Dec 2003 | -$196.77M(+81.2%) | -$41.03M(-52.5%) | -$152.64M(+6.2%) |
| Sep 2003 | - | -$86.42M(+88.7%) | -$143.69M(+58.4%) |
| Jun 2003 | - | -$45.80M(-322.2%) | -$90.72M(+37.6%) |
| Mar 2003 | - | $20.61M(-164.2%) | -$65.94M(-39.3%) |
| Dec 2002 | -$108.62M(+64.0%) | -$32.08M(-4.1%) | -$108.62M(+36.1%) |
| Sep 2002 | - | -$33.45M(+59.2%) | -$79.80M(+38.0%) |
| Jun 2002 | - | -$21.02M(-4.7%) | -$57.83M(+18.2%) |
| Mar 2002 | - | -$22.07M(+576.9%) | -$48.91M(+36.9%) |
| Dec 2001 | -$66.23M(+90.7%) | -$3.26M(-71.6%) | -$35.72M(-7.9%) |
| Sep 2001 | - | -$11.48M(-5.2%) | -$38.79M(-25.6%) |
| Jun 2001 | - | -$12.11M(+36.5%) | -$52.17M(+90.1%) |
| Mar 2001 | - | -$8.87M(+40.0%) | -$27.45M(-26.4%) |
| Dec 2000 | -$34.74M(-15.3%) | -$6.34M(-74.5%) | -$37.29M(+27.5%) |
| Sep 2000 | - | -$24.86M(-297.1%) | -$29.26M(+56.5%) |
| Jun 2000 | - | $12.61M(-167.4%) | -$18.70M(-55.6%) |
| Mar 2000 | - | -$18.71M(-1200.6%) | -$42.15M(+2.7%) |
| Dec 1999 | -$41.00M(+23.9%) | $1.70M(-111.9%) | -$41.04M(-25.8%) |
| Sep 1999 | - | -$14.30M(+31.9%) | -$55.34M(+27.7%) |
| Jun 1999 | - | -$10.84M(-38.4%) | -$43.34M(+2.5%) |
| Mar 1999 | - | -$17.60M(+39.7%) | -$42.30M(+27.8%) |
| Dec 1998 | -$33.10M(+67.2%) | -$12.60M(+447.8%) | -$33.10M(+21.2%) |
| Sep 1998 | - | -$2.30M(-76.5%) | -$27.30M(-11.7%) |
| Jun 1998 | - | -$9.80M(+16.7%) | -$30.90M(+37.3%) |
| Mar 1998 | - | -$8.40M(+23.5%) | -$22.50M(+13.1%) |
| Dec 1997 | -$19.80M(-50.5%) | -$6.80M(+15.3%) | -$19.90M(+17.1%) |
| Sep 1997 | - | -$5.90M(+321.4%) | -$17.00M(-2.3%) |
| Jun 1997 | - | -$1.40M(-75.9%) | -$17.40M(-54.6%) |
| Mar 1997 | - | -$5.80M(+48.7%) | -$38.30M(-4.3%) |
| Dec 1996 | -$40.00M(+86.0%) | -$3.90M(-38.1%) | -$40.00M(+8.4%) |
| Sep 1996 | - | -$6.30M(-71.7%) | -$36.90M(-1.6%) |
| Jun 1996 | - | -$22.30M(+197.3%) | -$37.50M(+55.0%) |
| Mar 1996 | - | -$7.50M(+837.5%) | -$24.20M(+13.1%) |
| Dec 1995 | -$21.50M(+22.2%) | -$800.00K(-88.4%) | -$21.40M(-16.1%) |
| Sep 1995 | - | -$6.90M(-23.3%) | -$25.50M(+13.3%) |
| Jun 1995 | - | -$9.00M(+91.5%) | -$22.50M(+18.4%) |
| Mar 1995 | - | -$4.70M(-4.1%) | -$19.00M(+8.6%) |
| Dec 1994 | -$17.60M(-980.0%) | -$4.90M(+25.6%) | -$17.50M(+348.7%) |
| Sep 1994 | - | -$3.90M(-29.1%) | -$3.90M(+44.4%) |
| Jun 1994 | - | -$5.50M(+71.9%) | -$2.70M(-235.0%) |
| Mar 1994 | - | -$3.20M(-136.8%) | $2.00M(+5.3%) |
| Dec 1993 | $2.00M(-123.5%) | $8.70M(-422.2%) | $1.90M(-120.0%) |
| Sep 1993 | - | -$2.70M(+237.5%) | -$9.50M(+5.6%) |
| Jun 1993 | - | -$800.00K(-75.8%) | -$9.00M(-10.9%) |
| Mar 1993 | - | -$3.30M(+22.2%) | -$10.10M(+20.2%) |
| Dec 1992 | -$8.50M(+66.7%) | -$2.70M(+22.7%) | -$8.40M(+20.0%) |
| Sep 1992 | - | -$2.20M(+15.8%) | -$7.00M(+16.7%) |
| Jun 1992 | - | -$1.90M(+18.8%) | -$6.00M(+9.1%) |
| Mar 1992 | - | -$1.60M(+23.1%) | -$5.50M(+7.8%) |
| Dec 1991 | -$5.10M(+18.6%) | -$1.30M(+8.3%) | -$5.10M(+4.1%) |
| Sep 1991 | - | -$1.20M(-14.3%) | -$4.90M(+2.1%) |
| Jun 1991 | - | -$1.40M(+16.7%) | -$4.80M(+6.7%) |
| Mar 1991 | - | -$1.20M(+9.1%) | -$4.50M(+4.7%) |
| Dec 1990 | -$4.30M | -$1.10M(0.0%) | -$4.30M(+34.4%) |
| Sep 1990 | - | -$1.10M(0.0%) | -$3.20M(+52.4%) |
| Jun 1990 | - | -$1.10M(+10.0%) | -$2.10M(+110.0%) |
| Mar 1990 | - | -$1.00M | -$1.00M |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual net profit?
- What is the all time high annual net income for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual net income year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly net profit?
- What is the all time high quarterly net income for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly net income year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM net profit?
- What is the all time high TTM net income for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM net income year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual net profit?
The current annual net income of VRTX is -$535.60M
What is the all time high annual net income for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual net profit is $3.62B
What is Vertex Pharmaceuticals Incorporated annual net income year-on-year change?
Over the past year, VRTX annual net profit has changed by -$4.16B (-114.80%)
What is Vertex Pharmaceuticals Incorporated quarterly net profit?
The current quarterly net income of VRTX is $913.00M
What is the all time high quarterly net income for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly net profit is $1.55B
What is Vertex Pharmaceuticals Incorporated quarterly net income year-on-year change?
Over the past year, VRTX quarterly net profit has changed by -$55.80M (-5.76%)
What is Vertex Pharmaceuticals Incorporated TTM net profit?
The current TTM net income of VRTX is -$535.60M
What is the all time high TTM net income for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM net profit is $4.02B
What is Vertex Pharmaceuticals Incorporated TTM net income year-on-year change?
Over the past year, VRTX TTM net profit has changed by -$4.16B (-114.80%)